GAS-Luc2 Reporter Cell Lines for Immune Checkpoint Drug Screening in Solid Tumors
Open Access
Abstract
Recent studies highlight the integral role of the interferon gamma receptor (IFNγR) pathway in T cell–mediated cytotoxicity against solid but not liquid tumors. IFNγ not only directly facilitates tumor cell death by T cells but also indirectly promotes cytotoxicity via myeloid phagocytosis in the tumor microenvironment. Meanwhile, full human ex vivo immune checkpoint drug screening remains challenging. We hypothesized that an engineered gamma interferon activation site response element luciferase reporter (GAS-Luc2) can be utilized for immune checkpoint drug screening in diverse ex vivo T cell–solid tumor cell co-culture systems. We comprehensively profiled cell surface proteins in ATCC’s extensive collection of human tumor and immune cell lines, identifying those with endogenously high expression of established and novel immune checkpoint molecules and binding ligands. We then engineered three GAS-Luc2 reporter tumor cell lines expressing immune checkpoints PD-L1, CD155, or B7-H3/CD276. Luciferase expression was suppressed upon relevant immune checkpoint–ligand engagement. In the presence of an immune checkpoint inhibitor, T cells released IFNγ, activating the JAK-STAT pathway in GAS-Luc2 cells, and generating a quantifiable bioluminescent signal for inhibitor evaluation. These reporter lines also detected paracrine IFNγ signaling for immune checkpoint-targeted ADCC drug screening. Further development into an artificial antigen-presenting cell line (aAPC) significantly enhanced T cell signaling for superior performance in these ex vivo immune checkpoint drug screening platforms.Keywords
All Related Versions
This publication has 39 references indexed in Scilit:
- CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastomaImmunity, 2023
- Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancersCell Reports, 2022
- CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T CellsImmunity, 2020
- Immuno-oncology drug development forges on despite COVID-19Nature Reviews Drug Discovery, 2020
- Quantitative Proteomics of the Cancer Cell Line EncyclopediaCell, 2020
- Organoid Modeling of the Tumor Immune MicroenvironmentCell, 2018
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsCell, 2018
- Pharmacogenomic agreement between two cancer cell line data setsNature, 2015
- Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cellsTrends in Biotechnology, 2014
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012